Myxofibrosarcoma: Clinical Trials

6 trials for Myxofibrosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1
Phase 23Completed 1, Recruiting 1, Terminated 1

Follow Myxofibrosarcoma: new trials by email Literature Review of Myxofibrosarcoma trials Research Report on Myxofibrosarcoma

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma
Phase 1 / Phase 2RecruitingSt. Jude Children's Research Hospital1392024-03-272026-08-03
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor
Phase 1Active not recruitingJonsson Comprehensive Cancer Center142020-10-142026-03-10
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
DCC-3014, Avelumab - Sarcoma, Advanced Sarcoma
Phase 1CompletedMemorial Sloan Kettering Cancer Center322020-01-222025-08-28
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Phase 1 / Phase 2CompletedBioAtla, Inc.2452018-02-152025-09-23
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma
Phase 1CompletedOHSU Knight Cancer Institute162017-03-102023-08-16
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)1512015-11-302022-08-23

Narrower conditions

Dermatofibrosarcoma (6)  ·  Histiocytoma, Malignant Fibrous (5)  ·  Leiomyosarcoma (4)  ·  Neurofibrosarcoma (4)  ·  Sarcoma (4)  ·  Sarcoma, Synovial (4)  ·  Liposarcoma (3)  ·  Disorders of Sex Development (2)  ·  Fibrosarcoma (2)  ·  Hemangiosarcoma (2)  ·  Chondrosarcoma, Extraskeletal Myxoid (1)  ·  Glomus Tumor (1)  ·  Granular Cell Tumor (1)  ·  Hemangioendothelioma, Epithelioid (1)  ·  Histiocytoma, Angiomatoid Fibrous (1)

Broader conditions

Neoplasms by Histologic Type (6)  ·  Neoplasms, Connective Tissue (6)  ·  Neoplasms, Connective and Soft Tissue (6)  ·  Neoplasms, Fibrous Tissue (6)  ·  Histiocytoma (5)  ·  Neoplasms (5)  ·  Fibrosarcoma (4)  ·  Neoplasms, Muscle Tissue (4)  ·  Neoplasms, Nerve Tissue (4)  ·  Nervous System Diseases (4)  ·  Nervous System Neoplasms (4)  ·  Neurofibroma (4)  ·  Neuromuscular Diseases (4)  ·  Peripheral Nervous System Diseases (4)  ·  Peripheral Nervous System Neoplasms (4)

Interventions

Doxorubicin (2)  ·  pazopanib (2)  ·  BO-112 (1)  ·  Ifosfamide (1)  ·  Immune Checkpoint Inhibitors (1)  ·  Nivolumab (1)  ·  Proton Therapy (1)  ·  Radiation (1)  ·  Radiotherapy (1)  ·  avelumab (1)  ·  ribociclib (1)  ·  sapanisertib (1)  ·  selinexor (1)

Sponsors

BioAtla, Inc. (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  OHSU Knight Cancer Institute (1)  ·  St. Jude Children's Research Hospital (1)

Countries

United States (6)  ·  Hong Kong (1)  ·  Taiwan (1)

Top investigators

Jessica Gartrell, MD (1)  ·  Lara E Davis (1)  ·  Sandra D'Angelo, MD (1)  ·  Vishruth Reddy, MD, PhD (1)  ·  William D Tap (1)

Results publications

PMID 38579194

NIH funding

K08CA245181 (1), U10CA180821 (1)